CN1550160A - 碱性矿物质溶液、其制造方法以及利用其预防骨质疏松症的食物 - Google Patents
碱性矿物质溶液、其制造方法以及利用其预防骨质疏松症的食物 Download PDFInfo
- Publication number
- CN1550160A CN1550160A CNA2004100342984A CN200410034298A CN1550160A CN 1550160 A CN1550160 A CN 1550160A CN A2004100342984 A CNA2004100342984 A CN A2004100342984A CN 200410034298 A CN200410034298 A CN 200410034298A CN 1550160 A CN1550160 A CN 1550160A
- Authority
- CN
- China
- Prior art keywords
- composition
- weight
- content
- respect
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims abstract description 38
- 239000011707 mineral Substances 0.000 title claims abstract description 38
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 34
- 235000013305 food Nutrition 0.000 title description 5
- 238000002360 preparation method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 70
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 52
- 150000007524 organic acids Chemical class 0.000 claims abstract description 27
- 230000002265 prevention Effects 0.000 claims abstract description 22
- 241000206572 Rhodophyta Species 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 18
- 230000006872 improvement Effects 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 235000001497 healthy food Nutrition 0.000 claims description 11
- 108010001441 Phosphopeptides Proteins 0.000 claims description 10
- 239000005018 casein Substances 0.000 claims description 10
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 10
- 235000021240 caseins Nutrition 0.000 claims description 10
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 9
- 244000068988 Glycine max Species 0.000 claims description 9
- 235000010469 Glycine max Nutrition 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 7
- 244000001632 Acorus gramineus Species 0.000 claims description 4
- 235000013073 Acorus gramineus Nutrition 0.000 claims description 4
- 241000282994 Cervidae Species 0.000 claims description 4
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 4
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 4
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 4
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 4
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 4
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 4
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 4
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 4
- 240000000171 Crataegus monogyna Species 0.000 claims description 4
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 4
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 4
- 241000110637 Cuscuta chinensis Species 0.000 claims description 4
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 4
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 4
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 4
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 4
- 241000208688 Eucommia Species 0.000 claims description 4
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 241000112528 Ligusticum striatum Species 0.000 claims description 4
- 244000170916 Paeonia officinalis Species 0.000 claims description 4
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 4
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 4
- 241000405414 Rehmannia Species 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 239000012670 alkaline solution Substances 0.000 abstract 4
- 241000283690 Bos taurus Species 0.000 abstract 1
- 241000238371 Sepiidae Species 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- 229940029985 mineral supplement Drugs 0.000 abstract 1
- 235000020786 mineral supplement Nutrition 0.000 abstract 1
- 230000009469 supplementation Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 37
- 239000011575 calcium Substances 0.000 description 26
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 25
- 229910052791 calcium Inorganic materials 0.000 description 25
- 230000000694 effects Effects 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 16
- 210000002700 urine Anatomy 0.000 description 16
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 108010048734 sclerotin Proteins 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 8
- 239000011574 phosphorus Substances 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 6
- 235000011941 Tilia x europaea Nutrition 0.000 description 6
- 239000004571 lime Substances 0.000 description 6
- 238000000465 moulding Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000010941 cobalt Substances 0.000 description 3
- 229910017052 cobalt Inorganic materials 0.000 description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- VEPOHXYIFQMVHW-PVJVQHJQSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;(2s,3s)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 VEPOHXYIFQMVHW-PVJVQHJQSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000541656 Carex marina Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical class [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940039412 ketalar Drugs 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/882—Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及碱性矿物质溶液,其制造方法以及利用其的骨质疏松症预防以及改善用组合物。更详细地说,涉及将牛骨头、墨鱼骨头以及红藻类作为原料并添加有机酸而得到的碱性矿物质溶液,其制造方法以及利用碱性矿物质溶液的骨质疏松症的预防以及具有改善效果的组合物或者健康食品。本发明的碱性矿物质溶液含有大量人体所需要的各种无机物而用于无机物的补充品,本发明的骨质疏松症预防以及改善用组合物预防骨髓吸收以及骨髓无机物的损失,所以可使用于如骨质疏松症、衰退性骨髓疾病等的骨髓疾病的预防以及改善。
Description
技术领域
本发明涉及碱性矿物质溶液,其制造方法以及利用其预防和改善骨质疏松症的组合物。更详细地说,本发明涉及把牛骨头、墨鱼骨头以及红藻类作为原料添加有机酸并得到的碱性矿物质溶液,其制造方法以及利用碱性矿物质溶液预防和改善骨质疏松症的组合物或者健康食品。
背景技术
无机物活化碳水化合物、脂肪、蛋白质的代谢而促进活体的生理活性和成长,所以成为给所有营养素注入活性的原动力。人体所需的无机物钙(Ca)、磷(P)、钠(Na)、钾(K)、氯(Cl)、镁(Mg)、硫(S)等的量比较多,即一天需要吸收100mg以上,而需要铁(Fe)、钴(Co)、锌(Zn)、锰(Mn)、碘(I)、钼(Mo)、硒(Se)、氟(F),铬(Cr)等的量很少。虽然只有极微量,但是无机物在能量、成长、体组织的维持、有助调整身体活动等方面起着重要的作用,并且无机物的不足在身体组织和代谢的进行上导致持续的问题。
无机物的活体利用率根据微量营养素的摄取标准、化学形态、吸收增进因素的妨碍物质和其他营养素的相互作用而不同,因此对无机物的适当摄取量和缺乏的研究很活跃。
无机物利用率的影响因素根据如年龄,性别,健康以及疾病状态,怀孕与否的内源因素和如蛋白质,脂肪,碳水化合物,食物纤维以及维生素摄取状态的外源因素来分类,尤其是以谷类为主食或频繁利用精制的谷类制造便利食品的现代人来说需要摄取适当标准以上的无机物。
人体代谢之前起重要作用的无机物中的钙对骨头的石灰化和血液凝固有影响,镁具有肌肉和神经的兴奋抑制功能,铁是血色素的构成物质,其作为各种酵素的辅酶起作用,锌是RNA聚合酶的辅酶,铜是过氧化物歧化酶的辅酶,钴是预防以及改善恶性贫血的很重要的维生素B12的构成物质等,因此,无机物对各种疾病的诱发起很重要的作用。
工业发达的社会,饮食生活方便化的现代人对钙的要求量在增加,但却对此出现了很多不足症状。尽管增加了钙的摄取量,但是,由于钙的实际吸收率低而使其在有效性上存在问题。为了解决这些问题,最近各国在开发不同化学形态的各种金霉素或以蛋壳、牡蛎壳等为核心的钙强化食品、钙补充剂和体内钙利用性增进物质以及对这些钙供应源的有效性和影响效果通过动物实验进行了不同的比较研究。
骨质疏松症是骨组织的石灰质减少而消弱骨头的致密性,由此使骨髓腔发展为加宽状态的症状,其使骨头变得脆弱,所以即使小的冲击也容易发生骨折。骨梁受遗传因素、营养摄取、荷尔蒙的变化、运动以及生活习惯的差异等各种因素的影响,骨质疏松症的原因有老龄、运动不足、低体重、吸烟、低钙饮食、闭经、卵巢切除等。另外虽然有个人差异,但黑人比白人的骨再吸收能力低而骨梁更高,骨梁大概在14~18岁的时候最高,到晚年每年减少约1%。尤其是女性从30岁以后开始持续发生骨减少,到了闭经期,由于荷尔蒙的变化而发生急速的骨减少。
像这样的骨质疏松症虽然在程度上有所差异,但是对于老年层,尤其是对闭经期以后的女性来说是无法避免的症状。在先进的国家,随着老龄化人口的逐渐增加,人们对骨质疏松症以及其治疗剂越来越关心。在全世界已经形成了与骨质疾病相关的约1300亿美元的市场并预想今后更多,所以世界各研究机关和制药公司对骨质疾病治疗剂的开发投入很多。
发明内容
为了实现上述目的,本发明的目的在于提供人体大量需要的含有钙、镁、磷、钠、锌等无机物的碱性矿物质溶液以及其制造方法。
本发明的另一个目的在于提供具有骨质疏松症预防以及改善效果的组合物以及健康食品。
具体实施方式
为了实现上述的目的,本发明提供包括牛骨、墨鱼骨头、红藻类、有机酸以及纯净水构成的碱性矿物质溶液。
本发明还提供包括(a)本发明的碱性矿物质溶液,(b)天然药物;(c)黄太;(d)黑豆;(e)香菇;(f)酪蛋白磷肽(phospeptide);以及(g)DHA(二十二碳六烯酸)构成的骨质疏松症预防以及改善用组合物。
本发明还提供碱性矿物质溶液的制造方法,该方法包括(a)粉碎牛骨、墨鱼骨头以及红藻类的粉末化的步骤;(b)在1000至2000℃加热上述粉末的步骤;(c)冷却上述加热粉末的步骤;(d)在上述冷却的粉末里添加纯净水后溶液化的步骤;(e)在上述溶液里添加有机酸的步骤;(f)把上述添加有机酸的溶液在120至150℃的加压抽出机里溶液化的步骤;以及(g)冷却上述溶液后过滤的步骤。
以下更详细地说明本发明。
本发明者在研究无机物溶液以及骨质疏松症预防剂或者改善剂的过程中,确认在烧成的牛骨、墨鱼骨头以及红藻类后得到的无机物里添加处理有机酸并制造溶液的结果是,溶液大量含有各种矿物质,利用此溶液的组合物对骨质疏松症预防以及改善具有效果,并根据这些完成了本发明。
根据本发明的碱性矿物质溶液包括牛骨、墨鱼骨头、红藻类、有机酸以及纯净水。牛骨、墨鱼骨头、红藻类以在高温烧成粉末的形态利用。红藻类是和绿藻类、褐藻类等一起属于海藻类,海苔、琼脂等属于红藻类。牛骨、墨鱼骨头以及红藻类的含量相对于溶液为2至10重量%为好。牛骨、墨鱼骨头以及红藻类的含量未满2重量%时,无机物的供应效果很少而不适当;超过10重量%时,无机物的溶解达到饱和状态而不增加溶解度所以不适当。
上述添加的有机酸最好是由醋酸、乳酸以及柠檬酸构成的组中选择的一种以上的有机酸。并且有机酸的含量相对于溶液为2至10重量%为好。上述有机酸的含量未满2重量%时,没有增加无机物的溶解度而不适当;超过10重量%时,酸性性质强而不适当。
以下,详细说明根据本发明的碱性矿物质溶液的制造方法。
第一,粉碎牛骨、墨鱼骨以及红藻类后进行微细粉末化。
第二,在1000至1200℃下加热烧成粉末,通过加热步骤完全燃烧并消除各种细菌,不纯物质等后只剩下无机物。像这样的加热步骤最好实施30分钟至1小时。上述加热步骤的时间未满30分钟时,无机物烧成程度低而不适当,而超过1小时时,无机物烧成程度不会再增加而不适当。
第三,把加热的粉末冷却到室温后,添加纯净水进行溶液化。粉末物质的含量相对于整个溶液最好是2至10重量%。粉末的含量未满2重量%时,无机物的供应效果很少而不适当,而超过10重量%时,无机物的溶解达到饱和状态而不增加溶解度所以也不适当。
第四,在制造的溶液里添加有机酸。有机酸最好是由醋酸、乳酸以及柠檬酸构成的组中选择的一种以上的有机酸。并且有机酸的含量相对于整个溶液为2至10重量%为好。上述有机酸的含量未满2重量%时,无机物的溶解低而不适当,而超过10重量%时,不仅没有增加无机物的溶解度反而增加了酸性性质而不适当。
第五,把添加有机酸的溶液在120至150℃的加压抽出机里进行溶液化。该溶液化步骤最好实施20分钟至1小时。该溶液化步骤的时间未满20分钟时,几乎没有溶液化的效果而不适当,而超过1小时时没有增加无机物的溶解程度而不适当。
第六,冷却溶液后过滤。
本发明的碱性矿物质溶液以含有牛骨、墨鱼骨头、红藻类、有机酸为特点。牛骨、墨鱼骨头、红藻类、有机酸以外的甜味佐料或酸佐料以及它们的添加量并没有特别限制,本领域的技术人员可以容易地选定。
本发明提供的碱性矿物质溶液或者包括本发明的制造方法制造的碱性矿物质溶液;天然药物;黄太;黑豆;香菇;酪蛋白磷肽;以及DHA(二十二碳六烯酸)的骨质疏松症预防以及改善用组合物。
上述天然药物优选选自由杜仲、鹿角、山药、山楂、菟丝子、白茯苓、熟地黄、石菖蒲、黄芪、芍药、川芎、当归、甘草以及它们的混合物构成的组。并且上述天然药物的含量相对于整个组合物为0.1至27.5重量%为好。天然药物的含量超过27.5重量%时,制丸不容易成型等而不适当。
上述黄太的含量相对于整个组合物优选为0.1至20重量%。黄太的含量超过20重量%时,制丸不容易成型而不适当。
上述黑豆的含量相对于整个组合物优选为0.1至20重量%。黑豆的含量超过20重量%时,制丸不容易成型而不适当。
上述香菇的含量相对于整个组合物优选为0.1至10重量%。香菇的含量超过10重量%时,制丸不容易成型而不适当。
上述酪蛋白磷肽的含量相对于整个组合物优选为0.1至1.2重量%。酪蛋白磷肽的含量超过1.2重量%时,添加酪蛋白磷肽的效果不会再增加而不适当。
上述DHA(二十二碳六烯酸)的含量相对于整个组合物优选为0.1至0.3重量%。DHA的含量超过0.3重量%时,添加DHA的效果不会再增加而不适当。
本发明还提供把本发明的骨质疏松症预防以及改善用组合物作为有效成份的健康食品。把本发明的骨质疏松症预防以及改善用组合物作为主成份的健康食品有汁、茶、果冻、果汁等健康食品以及嗜好品,健康食品的剂型以药丸为好。
以下用实施例以及实验例详细说明本发明。
但是下述的实施例只是本发明的一个实施例,本发明并不限于下述的实施例。
(实施例1)
1、利用粉碎机微细粉末化洗涤的牛骨1kg,墨鱼骨头1kg以及红藻类1kg。
2、将粉碎的粉末在1000~1200℃加热烧成30分钟。
3、将加热的粉末在室温冷却。
4、在冷却的粉末50g里添加纯净水10而制造成溶液。
5、在上述溶液里添加50g醋酸且在2小时的减压下慢慢搅拌并使无机物溶液化。
6、把添加上述有机酸的溶液在130℃的加压抽出机进行30分钟的溶液化。
7、把上述溶液在室温冷却后,用过滤纸进行过滤,得到碱性矿物质溶液。
(实施例2)
1、把杜仲、鹿角、山药、山楂、菟丝子、白茯苓、熟地黄、石菖蒲、黄芪、芍药、川芎、当归、甘草各5g放入到上述实施例1制造的1kg碱性矿物质溶液里并在100℃提取5小时后进行过滤并减压浓缩后,将浓度调整到20~25白利糖度。
2、其后添加黄太20g,黑豆粉末20g,香菇粉末10g,酪蛋白磷肽12g,以及DHA 3g后制造组合物。
(实施例3)
1、混合,搅拌上述组合物后,用制丸机成型。
2、成型丸在40~50℃的干燥器里干燥到水分含量为8%以下。
(实验例1)
根据食品工典的微量成分试验法,对上述实施例1制造的碱性矿物质溶液的钙等无机物的9个项目进行含量分析。
如下表1显示碱性矿物质溶液的含量分析结果。
【表1】
无机物 | 含量(mg/100g) |
钙 | 1300 |
镁 | 125 |
磷 | 107 |
钠 | 1002 |
钾 | 285 |
锌 | 86 |
铜 | 75 |
锰 | 29 |
钴 | 18 |
如上述表1所示,根据本发明的碱性矿物质溶液含有大量无机物。
(实验例2)
以下,为了调查本发明的组合物对预防和改善骨质疏松症的效果,利用实施例2制造的组合物进行如下试验。
1、实验方法
(1)实验材料
用上述实施例2制造的组合物进行下面的实验。
(2)临床对象动物以及切除卵巢手术
给Sparque-Dauley系的雌性白色老鼠充分供应固形饲料和水并将在约三个星期的实验环境下适应后的体重为200g左右的各10只老鼠分成正常组组(卵巢非切除组),对照组(卵巢切除组,基本饲料),实验组(卵巢切除组,基本饲料和试验材料)。
切除卵巢手术过程如下。
腹部服药克他命1ml/kg(体重)后麻醉白色老鼠。麻醉后用电剃须刀消除背部部位的毛并用70%的酒精消毒。首先沿着白色老鼠的背部下端部位脊髓线约3cm左右的皮肤组织利用解剖刀切开并在位于卵巢的腹膜两侧切开1.5cm以后切除卵巢。对照组,实验组首先切除左侧卵巢而正常组不切除卵巢并缝合。手术一天以后服抗生素之后给约四个星期的恢复期。
(3)饲料组合物的投入
给正常组、对照组以及实验组投入组合物如表2。
使用于临床的白色老鼠以一日饲料投入量是60g/kg(体重)为标准,白色老鼠的一日饲料摄取量是确定白色老鼠3天摄取的饲料后求平均。组合物饲料投入60天后分析骨质疏松症的缓和效果。
【表2】
适用组 | 饲料组合物 |
正常组(非切除卵巢组) | 基本饲料100% |
实验组(切除卵巢组) | 基本饲料60重量%+实施例2的组合物40重量% |
对照组(切除卵巢组) | 基本饲料100% |
(4)血清成分的变化
①抽血以及血清分离
切除卵巢的第60天给每一只白色老鼠腹部内注射1.0ml(Ketalar),麻醉后心脏抽血并把血液在室温放置30分钟后在3000rpm离心分离15分钟而分离血清。
②血清中测定骨石灰(Osetocalcine)
测定血清中骨石灰的试剂是使用ELSA-OSETO试剂盒(CISbiointernational,France),机器使用ICN生物制药(ICN biomedicals,ISOMEDIC 10/600,USA)。
③测定血清中的钙
测定血清中钙的试剂是使用钙-HRII试剂盒(Wako pure chemicalindustries.Ltd.,JAPAN),机器使用日立747(自动化学分析仪,JAPAN)。
④测定血清中碱性磷酸酶(ALP)
测定血清中碱性磷酸酶活性度的试剂使用自动分析机ALP测定用试剂(牙山制药,韩国),机器使用日立747(自动化学分析仪,JAPAN)。
⑤测定血清中磷
使用自动分析机测定血清中的磷活性度的试剂磷测定用试剂(牙山制药,韩国),机器使用日立747(自动化学分析仪,JAPAN)。
(5)尿的变化
①抽尿以及尿量测定
切除卵巢第59天,使每一只放入塑料制代谢笼子里的白色老鼠自由摄取水和饲料并抽出和计量24小时尿后,在3,000rpm离心分离15分钟后得到上层的尿。
②测定尿中肌酸酐
测定尿中肌酸酐的试剂使用肌酸酐试剂盒(Daiichi,JAPAN),机器使用日立747(自动化学分析仪,JAPAN)。
③测定尿中钙
测定尿中钙的试剂使用钙-HRII试剂盒(Wako pure chemicalindustries.Ltd.,JAPAN),机器使用日立747(自动化学分析仪,JAPAN)。
④测定尿中吡啶啉
测定尿中吡啶啉的试剂使用吡啶啉G-试剂盒(Metra biosystem.USA),机器使用Pasteur ELISA system(LP400 LP35)。
2、实验结果
(1)血清成分的变化
实验切除老鼠的卵巢时增加骨小梁的骨芽细胞和破骨细胞的数量且破骨细胞的活动性实现骨芽细胞的活动性而减少骨质的量。但是女性荷尔蒙雌激素的投入抑制骨芽细胞和破骨细胞的增加。
切除卵巢后的骨质减少带来钙和血清内的骨质更换率的指标骨石灰、钙、碱性磷酸酶等的上升。
本发明者切除成熟的白色老鼠的卵巢后,由于雌激素的缺乏诱发骨质疏松症以后,将上述实施例2的组合物投入60天,然后测定血清中骨石灰、钙、(ALP)以及磷酸的含量。
骨质无机物代谢的指标骨石灰比对照组增加很多而具有切除卵巢而引起骨质更换率变化的抑制效果。
血清中的钙以及磷浓度在正常组,对照组,实验组里无变化。
对骨质疾病患者来说骨质新生活动的有用指标ALP在实验组明显的增加而具有骨质新生效果。
如下表3是以卵巢切除诱发的白色老鼠的血清成分的变化。
【表3】
血清成分 | 正常组 | 对照组 | 实验组 |
骨石灰(mg/l) | 0.21 | 0.09 | 0.18 |
钙(mg/dl) | 10.5 | 10.4 | 10.5 |
ALP(IU/l) | 192 | 283 | 410 |
磷(mg/dl) | 7.2 | 7.3 | 7.4 |
(2)尿的变化
如下表4是以卵巢切除诱发的白色老鼠的尿成分变化。
【表4】
尿成分 | 正常组 | 对照组 | 实验组 |
尿量(ml) | 3.6 | 10.2 | 3.9 |
脱氧吡啶啉/肌酸酐(nM/mM | 20.3 | 17.6 | 10.5 |
钙/肌酸酐(mg/g) | 32.4 | 68.5 | 29.8 |
24小时之间的尿量是实验组和正常组具有类似的水平,对照组明显的低而期待对骨质疏松症具有改善的效果。
脱氧吡啶啉主要存在骨质里,尿中的排出是成为骨质吸收的指标,脱氧吡啶啉/肌酸酐比是在实验组里减少,钙/肌酸酐比是在对照组减少,本实验使用的组合物防止骨质吸收以及骨质无机物的损失,而具有减少尿中脱氧吡啶啉和钙的排出量。
工业应用性
如上所述,本发明的碱性矿物质溶液含有大量人体所需的各种无机物而可利用为无机物的补充品。
本发明的骨质疏松症预防以及改善用组合物防止骨质吸收以及骨质无机物损失,所以使用于如骨质疏松症、变性骨质疾病等骨质疾病的预防以及改善上,并且无毒性而以健康食品广泛利用。
Claims (30)
1、碱性矿物质溶液,其含有牛骨头、墨鱼骨头、红藻类、有机酸以及纯净水。
2、根据权利要求1的碱性矿物质溶液,其特征在于,所述有机酸选自由醋酸、乳酸以及柠檬酸构成的组。
3、根据权利要求1的碱性矿物质溶液,其特征在于,牛骨头、墨鱼骨头以及红藻类的含量相对于溶液为2至10重量%。
4、根据权利要求1的碱性矿物质溶液,其特征在于,所述有机酸的含量相对于溶液为2至10重量%。
5、骨质疏松症预防以及改善用组合物,其含有(a)权利要求1至权利要求4中任何一项所述的碱性矿物质溶液;(b)天然药物;(c)黄太;(d)黑豆;(e)香菇;(f)酪蛋白磷肽;以及(g)二十二碳六烯酸。
6、根据权利要求5的组合物,其中所述天然药物选自杜仲、鹿角、山药、山楂、菟丝子、白茯苓、熟地黄、石菖蒲、黄芪、芍药、川芎、当归、甘草以及它们的混合物构成的组。
7、根据权利要求5的组合物,其中所述黄太的含量相对于整个组合物为0.1至20重量%。
8、根据权利要求5的组合物,其中所述黑豆的含量相对于整个组合物为0.1至20重量%。
9、根据权利要求5的组合物,其中所述天然药物的含量相对于整个组合物为0.1至27.5重量%。
10、根据权利要求5的组合物,其中所述香菇的含量相对于整个组合物为0.1至10重量%。
11、根据权利要求5的组合物,其中所述酪蛋白磷肽的含量相对于整个组合物为0.1至1.2重量%。
12、根据权利要求5的组合物,其中所述二十二碳六烯酸的含量相对于整个组合物为0.1至0.3重量%。
13、将权利要求5至权利要求12中的任何一项所述的骨质疏松症预防以及改善用组合物作为有效成分的健康食品。
14、根据权利要求13所述的健康食品,其剂型为药丸。
15、碱性矿物质溶液的制造方法,该方法包括:
(a)粉碎牛骨头、墨鱼骨头以及红藻类的粉末化的第一步骤;
(b)在1000至2000℃加热所述粉末的第二步骤;
(c)冷却所述加热粉末的第三步骤;
(d)在所述冷却的粉末里添加纯净水后溶液化的第四步骤;
(e)在所述溶液里添加有机酸的第五步骤;
(f)把添加所述有机酸的溶液在120至150℃的加压抽出机里溶液化的第六步骤;以及
(g)冷却所述溶液后过滤的第七步骤。
16、根据权利要求15所述的碱性矿物质溶液的制造方法,其中所述有机酸选自由醋酸、乳酸以及柠檬酸构成的组。
17、根据权利要求15所述的碱性矿物质溶液的制造方法,其中所述(d)步骤的粉末含量相对于溶液为2至10重量%。
18、根据权利要求15所述的碱性矿物质溶液的制造方法,其中在所述(e)步骤添加的有机酸的含量相对于溶液为2至10重量%。
19、根据权利要求15所述的碱性矿物质溶液的制造方法,其中所述(b)步骤进行30分钟至1小时。
20、根据权利要求15所述的碱性矿物质溶液的制造方法,其中所述(f)步骤进行20分钟至1小时。
21、骨质疏松症预防以及改善用组合物,其包含(a)根据权利要求15至权利要求20中任何一项所述的制造方法制造的碱性矿物质溶液;(b)天然药物;(c)黄太;(d)黑豆;(e)香菇;(f)酪蛋白磷肽;以及(g)二十二碳六烯酸。
22、根据权利要求21所述的骨髓疏松症预防以及改善用组合物,其中所述天然药物选自由杜仲、鹿角、山药、山楂、菟丝子、白茯苓、熟地黄、石菖蒲、黄芪、芍药、川芎、当归、甘草以及它们的混合物构成的组。
23、根据权利要求21所述的骨髓疏松症预防以及改善用组合物,其中所述黄太的含量相对于整个组合物为0.1至20重量%。
24、根据权利要求21所述的骨髓疏松症预防以及改善用组合物,其中所述黑豆的含量相对于整个组合物为0.1至20重量%。
25、根据权利要求21所述的骨髓疏松症预防以及改善用组合物,其中所述天然药物的含量相对于整个组合物为0.1至27.5重量%。
26、根据权利要求21所述的骨髓疏松症预防以及改善用组合物,其中所述香菇的含量相对于整个组合物为0.1至10重量%。
27、根据权利要求21所述的骨髓疏松症预防以及改善用组合物,其中所述酪蛋白磷肽的含量相对于整个组合物为0.1至1.2重量%。
28、根据权利要求21所述的骨髓疏松症预防以及改善用组合物,其中所述二十二碳六烯酸的含量相对于整个组合物为0.1至0.3重量%。
29、将权利要求21至权利要求28中的任何一项所述的骨质疏松症预防以及改善用组合物作为有效成分的健康食品。
30、根据权利要求29所述的健康食品,其剂型是药丸。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR0023431/2003 | 2003-04-14 | ||
KR1020030023431A KR20040088976A (ko) | 2003-04-14 | 2003-04-14 | 미네랄 보급용 알칼리 수용액을 이용한 골다공증 예방 및 개선용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1550160A true CN1550160A (zh) | 2004-12-01 |
Family
ID=34374066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004100342984A Pending CN1550160A (zh) | 2003-04-14 | 2004-04-12 | 碱性矿物质溶液、其制造方法以及利用其预防骨质疏松症的食物 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20050142209A1 (zh) |
KR (1) | KR20040088976A (zh) |
CN (1) | CN1550160A (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015033211A1 (en) * | 2013-09-05 | 2015-03-12 | Waitaki Biosciences | High osteocalcin microcrystalline hydroxyapatite for calcium supplement |
KR101692292B1 (ko) | 2016-06-20 | 2017-01-04 | 한남대학교 산학협력단 | 해조류 추출물을 유효성분으로 포함하는 골다공증 예방 또는 치료용 약학 조성물 |
KR102228685B1 (ko) | 2019-06-20 | 2021-03-15 | 한남대학교 산학협력단 | 프로폴리스 추출물을 유효성분으로 포함하는 골다공증 예방 또는 치료용 약학 조성물 |
KR102566496B1 (ko) | 2021-04-30 | 2023-08-11 | 한남대학교 산학협력단 | Msm, 칼슘 및 로즈마리 추출물을 유효성분으로 포함하는 골다공증 예방 또는 치료용 약학 조성물 |
-
2003
- 2003-04-14 KR KR1020030023431A patent/KR20040088976A/ko not_active Application Discontinuation
-
2004
- 2004-04-12 CN CNA2004100342984A patent/CN1550160A/zh active Pending
- 2004-04-14 US US10/823,915 patent/US20050142209A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20050142209A1 (en) | 2005-06-30 |
KR20040088976A (ko) | 2004-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101070993B1 (ko) | 법제유황을 이용한 단미사료 및 그 단미사료의 제조방법 | |
CN100350860C (zh) | 混合浓缩果汁、制备方法及其应用 | |
CN1864530A (zh) | 一种高寒山区作物精制健康食品及其加工工艺 | |
CN102132821A (zh) | 配方营养米及制备方法 | |
CN102871129A (zh) | 一种淮山复合营养米 | |
CN1550160A (zh) | 碱性矿物质溶液、其制造方法以及利用其预防骨质疏松症的食物 | |
CN1258538A (zh) | 治疗糖尿病和高血脂的蚕保健食品及其制备方法 | |
KR20190118720A (ko) | 사철쑥을 주성분으로 하는 기능성 및 친환경성 돼지사료용 보조제와 그 제조방법, 그리고 이를 이용한 돼지사육방법 및 그 돈육 | |
KR100863407B1 (ko) | 전복한방유황오리환의 제조 | |
CN1315392C (zh) | 一种豆奶粉及其制备方法 | |
CN111903822A (zh) | 一种补钙成长型夹心凝胶糖果及其制备方法 | |
CN1714653A (zh) | 一种面包及其制备方法 | |
KR20040081933A (ko) | 바이오 수삼(인삼) 침출차(당뇨 환자용) 제조방법 | |
KR20050080501A (ko) | 고혈압, 비만, 당뇨병환자를 위한 건강보조식품의 제조방법 | |
JP2005104953A (ja) | ミネラル補給用アルカリ水溶液、その製造方法及びそれを利用した骨多孔症予防及び改善用造成物(alkalinemineralsolution.Manufacturingmethodthereofandfoodforosteoporosispreventionusingthesame) | |
CN1381270A (zh) | 复合型多肽补钙冲剂及其制造工艺 | |
CN101342197A (zh) | 牡蛎壳活性钙胶囊的新制剂 | |
CN1759851A (zh) | 补钙制剂及制备方法 | |
CN1111052C (zh) | 通润丹 | |
KR101731898B1 (ko) | 한방소재를 이용한 고령친화적 고품질 멸치 칼슘제 | |
CN1181874C (zh) | 一种治疗急性脑出血的药物及其制备方法 | |
CN1299756C (zh) | 具有益胃作用的药物及其制备方法 | |
CN1232274C (zh) | 一种防治骨质疏松的药物组合物及其应用 | |
KR20040089000A (ko) | 미네랄 보급용 알칼리 수용액을 이용한 골다공증 예방 및개선용 건강식품 | |
CN1507898A (zh) | 一种含沙蚕的改善营养性贫血的保健品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |